The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: tacrolimus     Quarter: 2016Q3

Total Drug/Injury Combinations: 1,252     Number of Pages: 63

DRUGNAME PT EventCount
TACROLIMUS. Acute kidney injury 90 view events
TACROLIMUS. Headache 83 view events
TACROLIMUS. Kidney transplant rejection 63 view events
TACROLIMUS. Lymphocyte count decreased 58 view events
TACROLIMUS. Nausea 58 view events
TACROLIMUS. Urinary tract infection 56 view events
TACROLIMUS. Bronchopulmonary aspergillosis 55 view events
TACROLIMUS. Pyrexia 55 view events
TACROLIMUS. Haemoglobin decreased 53 view events
TACROLIMUS. Diarrhoea 52 view events
TACROLIMUS. Hypertension 52 view events
TACROLIMUS. Transplant rejection 51 view events
TACROLIMUS. Off label use 50 view events
TACROLIMUS. Hypoxia 48 view events
TACROLIMUS. Renal impairment 48 view events
TACROLIMUS. Blood creatinine increased 47 view events
TACROLIMUS. Lower respiratory tract infection bacterial 45 view events
TACROLIMUS. Cytomegalovirus infection 43 view events
TACROLIMUS. Diabetes mellitus 43 view events
TACROLIMUS. Drug interaction 43 view events

Total Drug/Injury Combinations: 1,252     Number of Pages: 63

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)